Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Committee To Probe Dosing Of MGI's Aquavan

This article was originally published in The Pink Sheet Daily

Executive Summary

May 7 agenda will look into providers untrained in anesthesia, too.

You may also be interested in...



Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."

MGI Pharma Files Aquavan NDA

Drug for mild to moderate sedation could achieve peak sales of $400 million, company tells "The Pink Sheet" DAILY.

IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns

The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067847

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel